Evidence map›Paper›PMID 29790086›Full record

ArticleJournal of endocrinological investigation2019

Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.

S Giannattasio, F Megiorni, V Di Nisio, A Del Fattore, R Fontanella, S Camero, C Antinozzi, C Festuccia, G L Gravina, S Cecconi and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. The botanical drug PBI-05204, a supercritical COFrontiers in pharmacology · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

S GiannattasioDepartment of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy.
F MegiorniDepartment of Paediatrics, Sapienza University of Rome, Rome, Italy.
V Di NisioDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
A Del FattoreMulti-Factorial Disease and Complex Phenotype Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
R FontanellaDepartment of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Rome, Italy.
S CameroDepartment of Paediatrics, Sapienza University of Rome, Rome, Italy.
C AntinozziDepartment of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy.
C FestucciaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1, 67100, L'Aquila, Coppito, Italy.
G L GravinaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1, 67100, L'Aquila, Coppito, Italy.
S CecconiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
C DominiciDepartment of Paediatrics, Sapienza University of Rome, Rome, Italy.
L Di LuigiDepartment of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy.
C CiccarelliDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1, 67100, L'Aquila, Coppito, Italy.
P De CesarisDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1, 67100, L'Aquila, Coppito, Italy.
A RiccioliDepartment of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Rome, Italy.
B M ZaniDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1, 67100, L'Aquila, Coppito, Italy.
A LenziDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
R G PestellPennsylvania Center for Cancer and Regenerative Medicine, Wynnewood, PA, 19096, USA.
A FilippiniDepartment of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Rome, Italy.
C CrescioliDepartment of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy.
V TomboliniDepartment of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
F MaramponDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1, 67100, L'Aquila, Coppito, Italy. f.marampon@gmail.com.
Sapienza University of Rome · ITUniversity of L'Aquila · ITForo Italico University of Rome · ITPoliclinico Umberto I · ITBambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in childhood, rarely affects adults, preferring male. RMS expresses the receptor for androgen (AR) and responds to androgen; however, the molecular action of androgens on RMS is unknown.

methodsHerein, testosterone (T) effects were tested in embryonal (ERMS) and alveolar (ARMS) RMS cell lines, by performing luciferase reporter assay, RT-PCR, and western blotting experiments. RNA interference experiments or bicalutamide treatment was performed to assess the specific role of AR. Radiation treatment was delivered to characterise the effects of T treatment on RMS intrinsic radioresistance.

resultsOur study showed that RMS cells respond to sub-physiological levels of T stimulation, finally promoting AR-dependent genomic and non-genomic effects, such as the transcriptional regulation of several oncogenes, the phosphorylation-mediated post-transductional modifications of AR and the activation of ERK, p38 and AKT signal transduction pathway mediators that, by physically complexing or not with AR, participate in regulating its transcriptional activity and the expression of T-targeted genes. T chronic daily treatment, performed as for the hormone circadian rhythm, did not significantly affect RMS cell growth, but improved RMS clonogenic and radioresistant potential and increased AR mRNA both in ERMS and ARMS. AR protein accumulation was evident in ERMS, this further developing an intrinsic T-independent AR activity.

conclusionsOur results suggest that androgens sustain and improve RMS transformed and radioresistant phenotype, and therefore, their therapeutic application should be avoided in RMS post puberal patients.

Indexed as

Cell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansReceptors, AndrogenRhabdomyosarcomaSignal TransductionTestosteroneReceptors, AndrogenTestosteroneAndrogen receptorRadioresistanceRhabdomyosarcomaSignal transductionTestosterone

Identifiers

PMID29790086
OpenAlexW2803774145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.